-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Most studies have shown that VEGFR tyrosine kinase inhibitors are not beneficial in adjuvant treatment of advanced renal cell carcinoma (RCC) .
VEGFR tyrosine kinase inhibitor does not have any benefit in adjuvant treatment of advanced renal cell carcinoma (RCC) VEGFR tyrosine kinase inhibitor does not have any benefit in adjuvant treatment of advanced renal cancer (RCC)
PROTECT (NCT01235962) is a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy of pazopanib in patients with locally advanced renal cancer who have a high risk of recurrence after nephrectomy.
Preliminary analysis showed that there was no significant difference in disease-free survival between pazopanib (600 mg) treatment and placebo.
Preliminary analysis showed that there was no significant difference in disease-free survival between pazopanib (600 mg) treatment and placebo.
The pazopanib group and placebo group were followed up for a median of 76 months and 77 months, respectively.
There was no significant difference in OS between pazopanib and placebo groups (hazard ratio 1.
Compared with patients with milder disease, patients with T4 stage have worse OS.
Compared with patients with milder disease, patients with T4 stage have worse OS.
Patients with a body mass index (BMI) ≥ 30 kg/m2 had better OS compared with patients with a lower BMI.
Patients with a body mass index (BMI) ≥ 30 kg/m2 had better OS compared with patients with a lower BMI.
Compared with those who relapsed within 2 years of treatment, patients who remained stable within 2 years of treatment had significantly better OS.
Compared with those who relapsed within 2 years of treatment, patients who remained stable within 2 years of treatment had significantly better OS.
It is not recommended to use pazopanib as an adjuvant treatment after resection of locally advanced renal cancer.
Original source:
Motzer Robert J, Russo Paul, Haas Naomi et al.
org/10.
1016/j.
eururo.
2020.
12.
029">Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial in this message
